120 results
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
25 Apr 24
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
6:46am
at Day 42. Dalzanemdor was generally well-tolerated, and there were no new safety signals observed. Based on the data, the Company does not plan any … is an open-label Phase 3 safety study of dalzanemdor in people with cognitive impairment associated with HD. The study is designed to evaluate the long-term
8-K
EX-99.1
SAGE
Sage Therapeutics Inc
17 Apr 24
Regulation FD Disclosure
6:35am
and there were no new safety signals observed
Topline data readouts from the Phase 2 studies in Huntington’s disease and Alzheimer’s disease are expected later … 42. Dalzanemdor (SAGE-718) was generally well-tolerated, and there were no new safety signals observed.
“We are disappointed by the results
8-K
EX-99.1
vgwa40wj57w
14 Feb 24
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-1.1
jddllbo
7 Nov 23
Entry into a Material Definitive Agreement
7:39am
424B5
fhm77
7 Nov 23
Prospectus supplement for primary offering
7:29am
8-K
EX-99.1
a2go8aw7v3u6 27n
7 Nov 23
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:46am
8-K
EX-99.1
kbxkn36w
7 Aug 23
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am
8-K
EX-99.1
84fusf12mppsgo
2 May 23
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
6:45am